Learn how iRhythm Technologies is addressing the challenges of undiagnosed arrhythmias, expanding into primary care, and even venturing into sleep disorder diagnostics.

With nearly 3 million patients served annually and more than 140 peer-reviewed studies, iRhythm is at the forefront of predictive healthcare. Subscribe for more insights into the medical device and diagnostics industry! #MedTech #iRhythm #AI #Wearables #HealthcareInnovation

Neil Klompas, the firm’s CEO, joins us for this episode of Let’s Talk Medtech to discuss how the company aims to accelerate the diagnosis of the disease and enhance autoimmune diagnostics for patients.

David Fischel, the St. Louis, MO-based company’s chairman and CEO, is featured in this episode of Let’s Talk Medtech to discuss Stereotaxis’ journey from surviving to thriving. The firm recently secured $50 million in funding and has had strong collaborations with NVIDIA.

Fischel talks about the company’s game plan and his thoughts on the future of surgical robotics.

Discover which medtech segment is experiencing explosive growth right now and learn why mid-tier companies are gaining unprecedented momentum in the marketplace. From industry health assessments to emerging market trends, this episode delivers essential insights for anyone invested in the future of medical technology.

Don't miss this comprehensive discussion that addresses the most pressing questions shaping today's medtech landscape.

In this value-packed episode, Paul reveals why successful fundraising requires a comprehensive, holistic approach rather than a narrow focus. He maps out proven strategies for medtech startups to attract and secure investment at various stages of development, drawing from his extensive experience in the industry.

Paul also shares remarkable insights into how MedTech Innovator has successfully connected over 700 promising companies with investors, helping transform innovative ideas into market-ready healthcare solutions.

Whether you're a medtech entrepreneur seeking funding, an investor looking for opportunities, or simply interested in the business of medical innovation, this episode delivers actionable wisdom from one of the industry's most respected voices.

Subscribe to Let's Talk Medtech for more expert conversations on navigating the complex world of medical technology development and commercialization.

Clemmer highlighted several significant achievements that have strengthened the company's position in both oncology and vascular care. He also describes how a crucial pivot helped redefine AngioDynamics.

Whether you're a medical device professional, healthcare provider, or industry investor, this episode delivers valuable insights to help you navigate the evolving medtech landscape. Subscribe for regular updates on industry news, expert interviews, and in-depth analysis of the technologies revolutionizing patient care.

CEO Chris Toth recently shared Vantive's ambitious vision, highlighting the firm's commitment to investing over $1 billion in digitally-enabled kidney care solutions. Toth discussed how this strategic separation has empowered the company to maintain its valuable legacy while gaining the flexibility to execute decisions more rapidly.

During the conversation, Toth also offered personal insights into his role as a medtech CEO and shared his deep passion for Vantive's mission to transform kidney care.

Omar : How are you?

Dana: Great. Thanks for having me.

Omar: I'm doing well, just a bit sleep-deprived with a newborn at home, but otherwise, all good.

Dana: Congratulations.

Dana: Thank you. So, Dana, it's been over a year since you took the reins at iCAD. How has the journey been so far?

Dana: Better than I expected, honestly. I joined ICAD's board over two years ago, initially thinking it was my dream role. But I saw an opportunity to contribute more directly given my background in cloud technologies and breast health. Jumping in has been fantastic—the team is great, and seeing our solutions in action, not just on paper, has been incredibly rewarding.

Omar: That's wonderful to hear. Before we dive into iCAD, let's talk about your time at Susan G. Komen. Can you share about your role there?

Dana: Sure, at Susan G. Komen, I served as the chief strategic and operations officer for nearly five years. My focus was enhancing direct patient engagement, ensuring initiatives like helplines, financial aid, and support resources were impactful and accessible. It was about making sure Komen's efforts directly benefited patients throughout their breast cancer journey.

Omar: How have your experiences at Komen influenced your approach at iCAD?

Dana: Three main takeaways: continuous learning, particularly in management and collaboration; leveraging technology like EMRs and research registries to enhance patient care; and fostering a culture of innovation, crucial for developing effective solutions in breast health.

Omar: It sounds like a wealth of knowledge to bring to iCAD. Speaking of which, let's touch on iCAD's use of AI in breast cancer detection. How is AI reshaping mammography?

Dana: AI has revolutionized mammography by enhancing accuracy and efficiency. Unlike human eyes, AI processes data at a granular level, making it a reliable second opinion for radiologists. Beyond cancer detection, we're exploring applications like detecting breast arterial calcification, offering a more holistic view of a patient's health.

Omar: That's impressive—AI as a precision tool in healthcare. Is it making mammogram results more understandable for patients?

Dana: Currently, AI primarily aids clinicians by providing trusted decision support. However, patients are becoming aware of AI's role and its potential to offer them clearer, faster insights into their health—a promising development we're exploring further.

Omar: Moving forward, iCAD has partnered with Google Health. What can you tell us about this collaboration?

Dana: Our collaboration with Google Health spans two key initiatives: integrating our technology into Google's cloud infrastructure for seamless healthcare operations, and jointly developing advanced AI algorithms. This includes creating an AI-powered second reader for mammograms, aiming to streamline diagnosis and reduce turnaround times, addressing the shortage of radiologists globally.

Omar: That's a significant step forward in leveraging technology for healthcare efficiency. While we await regulatory clearances, how do you see AI influencing patient care in the future?

Dana: AI is empowering patients with knowledge and enabling more informed healthcare decisions. It's part of a broader trend towards patient empowerment, where individuals actively engage in their health management—a positive shift we're committed to advancing at ICAD.

Omar: Your insights are invaluable. Looking back at your career journey, did you foresee technology playing such a pivotal role in healthcare?

Dana: Not initially, but my early interest in combining technology and sociology guided me towards leveraging tech for social impact. It's been a fulfilling journey seeing technology evolve from tax software to AI-driven healthcare solutions, empowering both patients and providers.

Anne-Gabrielle Haie, a partner with Steptoe LLP, answers questions about the AI Act and discusses its potential impact on the medical device industry in this all-new episode of Let's Talk Medtech.

Jennifer is the Chief Technology Officer, of Health Solutions at Flex, and drops by to shed some light on her keynote speech - Transforming the Future of Patient Care with Human Machine Interfaces. She'll also talk about how artificial intelligence is changing healthcare; why contract manufacturing is booming; and give tips on navigating the medical device industry in this season opener of Let's Talk Medtech.

Sarna joins us shortly before her keynote at BIOMEDevice Silicon Valley to discuss her journey into medtech and what it takes to be an entrepreneur in the industry.

Jan Makela, President and CEO, of Imaging at GE HealthCare, joins us to talk about the company's success and how it plans to finish out the year, in this exciting new episode.

Plus, he gives a preview of his upcoming keynote at BIOMEDevice Boston titled, "From Concept to Commercialization: It’s not brain surgery, or is it?"

Rachel will give her take on the landscape and how each player, patient, physician, and healthcare firm fit into the ecosystem.

We also talk about something that's been on everyone's minds lately - and that's artificial intelligence.

So join us for this episode of Let's Talk Medtech as we "crack" the digital health code.

The company recently completed enrollment for the TAILORED-AF clinical trial, which is a large-scale international trial involving multiple centers and physicians in five countries. The trial enrolled 374 patients who will be followed up for one year. The primary endpoint is freedom from AF after one procedure, with several secondary endpoints related to freedom from arrhythmia.

The co-founder of Volta Medical, Theophile Mohr-Durdez, joins this episode of Let's Talk Medtech to talk about the company's technology, long-term goals, and the unique skillset he brings to the table thanks to his experience on stage.

Scott along with Elucid's CEO Blake Richards joins us for this episode to talk about how the company is changing the way we view cardiovascular health.

Plus, Scott discusses his incredible career in this can't-miss episode.

Vignesh Shetty, Senior VP & General Manager of Edison AI And Platform at GE Healthcare, discusses why the digital platform is a difference maker.

DVir Cohen, CEO of Momentis Surgical, discusses the name change and how the Anovo Surgical system stands out in the surgical robotics space.

Kevin Sayer, Dexcom CEO, talks about the company's new position the space and all the hype surrounding the upcoming G7 CGM sensor. He also gives his thoughts on where CGM technology is headed in this incredible, can't miss conversation.

John Mastrototaro, CEO at Movano, joins the latest episode of Let's Talk Medtech to discuss that intersection of consumer and medical-grade wearables, and why he joined Movano. The Pleasanton, CA-based company is creating consumer products designed to deliver medical-grade data. Founded in 2018, the company recently announced that its first product will be a fitness ring designed specifically for women that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen, steps, and calories.

Movano is currently conducting clinical trials with its radio frequency-enabled technology and developing algorithms to add medical data, including non-invasive glucose monitoring and cuffless blood pressure, to its core product in the future. The company plans to execute accuracy studies to pursue FDA clearances on its vital signs monitoring capabilities including heart rate, SpO2, and respiration rate.

The Movano Ring is expected to be available through a beta release in the second half of 2022.

While the virus accelerated the adoption of technology in healthcare, it also illuminated existing gaps in digital care and leveraging patient data. And if not addressed, these gaps, along with other pressing healthcare issues like nursing shortages and the Great Resignation, will only further exacerbate healthcare’s existential problem. 

Dr. Bhaumik speaks about the true nature of the problem and gives some insight into potential solutions.

A special panel of medtech veterans discusses the mystique surrounding Holmes and the implications the trial could have on the industry in the future. Plus the panel gives some tips to entrepreneurs on how to avoid a "Theranos-like" situation.

Dr. Aklog stops by for an amazing conversation on how Lucid Diagnostics is making an impact in the detection of Esophageal Cancer.